(Phenylamino)pyrimidine-1,2,3-triazole derivatives as analogs of imatinib: searching for novel compounds against chronic myeloid leukemia

The enzyme tyrosine kinase BCR-Abl-1 is the main molecular target in the treatment of chronic myeloid leukemia and can be competitively inhibited by tyrosine kinase inhibitors such as imatinib. New potential competitive inhibitors were synthesized using the (phenylamino)pyrimidine-pyridine (PAPP) gr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Beilstein journal of organic chemistry Jg. 17; H. 1; S. 2260 - 2269
Hauptverfasser:	Pimentel, Luiz Claudio Ferreira, Hoelz, Lucas Villas Boas, Canzian, Henayle Fernandes, Branco, Frederico Silva Castelo, de Oliveira, Andressa Paula, Campos, Vinicius Rangel, Júnior, Floriano Paes Silva, Dantas, Rafael Ferreira, Resende, Jackson Antônio Lamounier Camargos, Cunha, Anna Claudia, Boechat, Nubia, Bastos, Mônica Macedo
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Germany Beilstein-Institut zur Föerderung der Chemischen Wissenschaften 01.09.2021 Beilstein-Institut
Schlagworte:	(phenylamino)pyrimidine-pyridine 1,2,3-triazole 1,3-dipolar cycloaddition BCR-ABL protein Binding sites Chemistry Chromosomes Chronic myeloid leukemia Confidence intervals Cytotoxicity Design Enzymes Full Research Paper Fusion protein Imatinib Kinases Leukemia Mutation Myeloid leukemia Protein-tyrosine kinase Triazoles (phenylamino)pyrimidine-pyridine chronic myeloid leukemia imatinib 1,2,3-triazole 1,3-dipolar cycloaddition
ISSN:	1860-5397, 2195-951X, 1860-5397
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!